Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darifenacin for warning time in overactive bladder
NCT00171145Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder syndrome (OAB) comparing Darifenacin with Placebo (2 arms). Primary endpoint: Change from baseline in warning time at 12 weeks. Started Apr 2004; status: completed.
02
Drugs
darifenacin
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT00171145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171145.